Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty

Circulation

Volumn 96, Issue 5, 1997, Pages 1445-1453

  King III, Spencer B ^a  

^a EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

Angioplasty; Glycoproteins; Platelets; Receptors

Indexed keywords

ABCIXIMAB; FIBRINOGEN; FIBRINOGEN RECEPTOR; TIROFIBAN;

ACUTE HEART INFARCTION; ADULT; ANGIOPLASTY; ARTICLE; ATHERECTOMY; BLEEDING; BOLUS INJECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DILATATION; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BLOCKING; STENT; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTOPENIA; THROMBOSIS; UNSTABLE ANGINA PECTORIS;

EID: 0343376106     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.cir.96.5.1445     Document Type: Article

References (28)

1. Harrington RA. Antithrombotic therapy during percutaneous coronary intervention. J Thromb Thrombolysis. 1995;2:21-28.
2. Boston DR, Malouf A, Barry WH. Management of intracoronary thrombosis complicating percutaneous transluminal coronary angioplasty. Clin Cardiol. 1996;19:536-542.
3. de Feyter PJ, van den Brand M, Jaarman G, van Domburg R, Serruys PW, Suryapranata H. Acute coronary occlusion during and after percutaneous transluminal coronary angioplasty. Circulation. 1991;83:927-936.
4. Lincoff AM, Popma JJ, Ellis SG, Hacker JA, Topol EJ. Abrupt vessel closure complicating coronary angioplasty: clinical, angiographic and therapeutic profile. J Am Coll Cardiol. 1992;19:926-935.
5. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330:956-961.
6. Théroux P, Kouz S, Roy L, Knudtson ML, Diodati JG, Marquis J, Nasmith J, Fung AY, Boudreault J, Delage F, Dupuis R, Kells C, Bokslag M, Steiner B, Rapold HJ. Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina. Circulation. 1996;94:899-905.
7. Willerson JT. Inhibitors of platelet glycoprotein IIb/IIIa receptors: will they be useful when given chronically? Circulation. 1996;94: 866-868.
8. Weitz JI, Califf RM, Ginsberg JS, Hirsh J, Theroux P. New antithrombotics. Chest. 1995;108(suppl):471S-485S.
9. Ezratty AM, Loscalzo J. New approaches to antiplatelet therapy. Blood Coagul Fibrinol. 1991;2:317-327.
10. Coller BS. Blockade of platelet GPIIb/IIIa receptors as an antithrombotic strategy. Circulation. 1995;92:2373-2380.
11. Lefkovits J, Topol EJ. Platelet glycoprotein IIb/IIIa receptor inhibitors in ischemic heart disease. Curr Opin Cardiol. 1995;10:420-426.
12. Tcheng JE. Enhancing safety and outcomes with the newer antithrombotic and antiplatelet agents. Am Heart J. 1995;130:673-679.
13. Frishman WH, Burns B, Bulent A, Alturk N, Altajar B, Lerrick K. Novel antiplatelet therapies for treatment of patients with ischemic heart disease: inhibitors of the platelet glycoprotein IIb/IIIa integrin receptor. Am Heart J. 1995;130:877-892.
14. Ellis SG, Bates ER, Schaible T, Weisman HF, Pitt B, Topol EJ. Prospects for the use of antagonists to the platelet glycoprotein IIb/IIIa receptor to prevent post-angioplasty restenosis and thrombosis. J Am Coll Cardiol. 1991;17(suppl B):89B-95B.
15. Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, Ivanhoe R, George BS, Fintel D, Weston M, Sigmon K, Anderson KM, Lee KL, Willerson JT, on behalf of the EPIC Investigators. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet. 1994;343:881-886.
16. Tcheng JG. Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. Am J Cardiol. 1996;78(suppl 3A):35-40.
17. Gates ER, McGillem MJ, Mickelson JK, Pitt B, Mancini GB. A monoclonal antibody against the platelet glycoprotein IIb/IIIa receptor complex prevents platelet aggregation and thrombosis in a canine model of coronary angioplasty. Circulation. 1991;84: 2463-2469.
18. Egbertson MS, Chang CTC, Duggan ME, Gould RJ, Halczenko W, Hartman GD, Laswell WL, Lynch JJ, Lynch RJ, Manno PD, Naylor AM, Prugh JD, Ramjit DR, Sitko GR, Smith RS, Turchi LM, Zhang GX. Non-peptide fibrinogen receptor antagonists, II: optimization of a tyrosine template as a mimic for Arg-Gly-Asp. J Med Chem. 1994;37:2537-2551.
19. Hartman GD. Tirofiban hydrochloride: platelet antiaggregatory GP IIb/IIIa receptor antagonist. Drugs Future. 1995;20:897-901.
20. Gould RJ, Chang CTC, Lynch RJ, Manno PD, Zhang GX, Bednar B, Friedman PA, Egbertson M, Turchi LM, Anderson PS, Hartman G'. MK-0383 is a potent non-peptide mimic of RGD that inhibits glycoprotein IIb/IIIa. Thromb Haemost. 1993;69:976. Abstract.
21. Peerlinck K, DeLepeleire I, Goldberg M, Farrell D, Barrett J, Hand E, Panebianco D, Deckmyn H, Vermylen J, Arnout J. MK-383 (L-700,462), a selective non-peptide platelet glycoprotein IIb/IIIa antagonist, is active in man. Circulation. 1993;88:1512-1517.
22. Lynch JJ, Cook JJ, Sitko GR, Holahan MA, Ramjit DR, Mellott MJ, Stranieri MT, Stabilito II, Zhang G, Lynch RJ, Manno PD, Chang T-C, Egbertson MS, Halczenko W, Duggan ME, Laswell WL, Vassallo LM, Shafer JA, Anderson PS, Friedman PA, Hartman GD, Gould RJ. Nonpeptide glycoprotein IIb/IIIa inhibitors, V: antithrombotic effects of MK-0383. J Pharmacol Exp Ther. 1995;272:20-32.
23. Kereiakes M, Kleiman S, Ambrose A, Cohen M, Rodriguez S, Palabrica T, Herrmann HC, Sutton JM, Weaver WD, McKee DB, Fitzpatrick V, Sax FL. Randomized, double-blind, placebo-controlled dose ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. J Am Coll Cardiol. 1996;27:536-542.
24. Barrett JS, Murphy G, Peerlinck K, Depeleire I, Gould RJ, Panebianco D, Hand E, Deckmyn H, Vermylen J, Arnout JJ. Pharmacokinetics and pharmacodynamics of MK-383, a selective nonpeptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men. Clin Pharmacol Ther. 1994;56:377-388.
25. Bovill EG, Terrin ML, Stump DC, Berke AD, Frederick M, Collen D, Feit F, Gore JM, Hillis LD, Lambrew CT, Leiboff R, Mann KG, Markis JE, Pratt CM, Sharkey SW, Sopko G, Tracy RP, Chesebro JH, for the TIMI Investigators. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Ann Intern Med. 1991;115: 256-265.
26. Horrigan MCG, Tcheng JE, Califf RM, Kitt M, Lorenz T, Sigmon K, Lincoff AM, Topol EJ, for the IMPACT II Investigators. Maximal benefit of integrelin platelet IIb/IIIa blockade 6-24 hours after therapy: results of the IMPACT-11 trial. J Am Coll Cardiol. 1996;27(suppl A):55A. Abstract.
27. Konstantopoulos K, Kamat SG, Schafer AI, Bañez EI, Jordan R, Kleiman NS, Hellums JD. Shear-induced platelet aggregation is inhibited by in vivo infusion of an anti-glycoprotein IIb/IIIa antibody fragment, c7E3 Fab. Circulation. 1995;91:1427-1431.
28. Mark DB, Talley JD, Topol EJ, Bowman L, Lam LC, Anderson KM Jollis JG, Cleman MW, Lee KL, Aversano T, Untereker WJ, Davidson-Ray L, Califf RM, for the EPIC Investigators. Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. Circulation. 1996;94:629-635.